• Aeon has raised €8.2M in seed funding to expand its AI-powered platform that detects over 500 health risks through full-body diagnostics.
  • Backed by insurers and investors like Concentric and Calm/Storm, Aeon is scaling preventive care across Switzerland, Germany, and the UK.

Swiss healthtech startup Aeon has raised €8.2 million in seed funding to scale its AI-driven platform for early disease detection across Europe. 

The round was led by London-based Concentric, with support from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and angel investor Daniel Gutenberg.

Founded in 2023, Aeon aims to shift healthcare from reactive treatment to proactive risk management. The platform combines full-body MRI, blood biomarker analysis, and genetic testing into a single 60-minute check-up.

With this multi-modal approach, Aeon claims it can detect and predict over 500 diseases and risks with clinical accuracy.

CEO and founder Tim Seithe said, “We’re redefining preventive care by shifting it from reactive checks to proactive, personalised health management. Our approach goes beyond early disease detection — we’re tackling one of preventive medicine’s biggest challenges: false positives.”

Since its launch, Aeon has maintained a 0% false positive rate in clinical-grade follow-ups, a notable achievement in a field often plagued by overdiagnosis. 

The AI system works across three levels: automated imaging analysis, cross-validation of data sources, and predictive modelling to create individualised health risk profiles.

Moreover, Aeon's technology has already led to early diagnoses of conditions like kidney cancer and Alzheimer’s in asymptomatic patients. In one case, a 56-year-old man’s undiagnosed cancer was caught through a single scan, enabling life-saving intervention.

Backed by insurers like KPT, Aeon is reportedly the first health platform in Switzerland offering full-body preventive check-ups eligible for insurance reimbursement up to 80% depending on the plan.

“Aeon is not just another testing solution,” said Alex Stroud, Principal at Concentric. “Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market. That rare combination of clinical rigour and commercial scalability is what makes this team so exciting.”

The fresh capital will support Aeon’s expansion across Switzerland, Germany, and the UK, with plans to open over 10 new clinical locations.

The company also intends to strengthen partnerships with insurers and employers to make preventive care more accessible.

Edited by Harshajit Sarmah